Annelot J. Van Rossum
Amsterdam, NH, Netherlands
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 17 publications
PI3K Inhibition in Combination with Tamoxifen in Patients with Metastatic HR+/HER2- Breast Cancer: Clinical and Circulating Tumor DNA Results.
Journal: Clinical cancer research : an official journal of the American Association for Cancer Research
Published: July 30, 2025
Immunohistochemical biomarkers to predict adjuvant chemotherapy response in patients with early breast cancer in the MATADOR trial (BOOG 2005-02).
Journal: Breast (Edinburgh, Scotland)
Published: April 18, 2025
Label-efficient computational tumour infiltrating lymphocyte assessment in breast cancer (ECTIL): multicentre validation in 2340 patients with breast cancer.
Journal: The Lancet. Digital health
Published: July 31, 2024
Daily Oral Ibandronate With Adjuvant Endocrine Therapy in Postmenopausal Women With Estrogen Receptor-Positive Breast Cancer (BOOG 2006-04): Randomized Phase III TEAM-IIB Trial.
Journal: Journal of clinical oncology : official journal of the American Society of Clinical Oncology
Published: April 20, 2022
Differential Survival and Therapy Benefit of Patients with Breast Cancer Are Characterized by Distinct Epithelial and Immune Cell Microenvironments.
Journal: Clinical cancer research : an official journal of the American Association for Cancer Research
Published: April 19, 2021
Carboplatin-Cyclophosphamide or Paclitaxel without or with Bevacizumab as First-Line Treatment for Metastatic Triple-Negative Breast Cancer (BOOG 2013-01).
Journal: Breast care (Basel, Switzerland)
Published: February 01, 2020
Tumour-infiltrating lymphocytes (TILs) and BRCA-like status in stage III breast cancer patients randomised to adjuvant intensified platinum-based chemotherapy versus conventional chemotherapy.
Journal: European journal of cancer (Oxford, England : 1990)
Published: August 30, 2019
POSEIDON Trial Phase 1b Results: Safety, Efficacy and Circulating Tumor DNA Response of the Beta Isoform-Sparing PI3K Inhibitor Taselisib (GDC-0032) Combined with Tamoxifen in Hormone Receptor Positive Metastatic Breast Cancer Patients.
Journal: Clinical cancer research : an official journal of the American Association for Cancer Research
Published: February 21, 2019
Adjuvant dose-dense doxorubicin-cyclophosphamide versus docetaxel-doxorubicin-cyclophosphamide for high-risk breast cancer: First results of the randomised MATADOR trial (BOOG 2004-04).
Journal: European journal of cancer (Oxford, England : 1990)
Published: July 06, 2018
FOXA1 levels are decreased in pleural breast cancer metastases after adjuvant endocrine therapy, and this is associated with poor outcome.
Journal: Molecular oncology
Published: April 06, 2018
Last Updated: 09/26/2026